Recently, it has been shown that elevated concentrations of copeptin are associated with worse outcome in COVID-19 patients with SARS-CoV-2 infection (Gregoriano et al., 2021) and may discriminate between patients with COVID-19 and patients with community-acquired pneumonia (Kuluöztürk et al., 2021). This evidence concerns the gene AVP and COVID-19.